VP LiquidBiopsy Systems
Dr. M. William Audeh currently serves as medical director of the Wasserman Breast Cancer Risk Reduction Program, Cancer Institute; director, cancer clinical quality improvement, hematology/oncology; and medical director, outpatient cancer center, Cancer Institute at Cedars-Sinai. His research is focused on treatment and prevention of breast cancer using molecular profiling of breast, ovarian and colorectal cancers to determine personalized treatment strategies with targeted therapies; clinical trials with genetically targeted therapies; breast cancer risk reduction based on personalized risk assessment (genetics, hormonal and exposure history, diagnostic testing, etc.) and appropriate risk-reducing interventions.
Dr. Audeh holds an M.D. from the University of Iowa School of Medicine. He completed his hematology/medical oncology fellowship and his residency at Stanford University Medical Center, where he was chief resident. Dr. Audeh also holds an M.S. degree in genetics from the University of Minnesota.
Dr. Michele Carpenter has dedicated her professional practice entirely to breast cancer diagnosis and care. She is currently the Program Director for the Breast Program at St. Joseph’s Center for Cancer Prevention and Treatment in Orange, Calif.
Dr. Carpenter earned her M.D. from Georgetown University. After General Surgery residency at Balboa Naval Hospital in San Diego, CA, she spent one year aboard the USS Acadia as the Chief Medical Officer. She then worked for Scripps Clinic Medical Group for 11 years where she was the Breast Program director. During her time in San Diego, she held the position of Medical Director of Susan G Komen Grant for the Breast Cancer Coalition as well as member of the Advisory Committee for the Scripps Clinic Advisory Board and American Cancer Society Breast Health Initiative Team. She was also a Clinical Instructor and Lecturer for the BCEDP Proficiency in Breast Examination Course for California Department of Health Services, and a Clinical Advisor and Consultant for Clinical Breast Protocols for the Cancer Detection Section of California Department of Health Services, and a Board Member of the American Cancer Society Breast Health Initiative Team. She has continued her association with San Diego breast care with her role as the Medical Director of the LBL Breast Cancer Support Group. She has also been president of San Diego Society of General Surgeons and San Diego Surgical Society.
She continues to be a reviewer and a member of the Ultrasound Committee for the American Society of Breast Surgeons, and has coauthored and participated as the principle investigator for several studies in IORT for breast cancer and cooperative group trials at the center. She also serves as the St. Joseph Hospital Medical Staff Secretary Treasurer, the Co-president of Women Doctors of Orange County and has been Chairman of Surgery as well as General Surgery and the Quality Enhancement Committee at St. Joseph Hospital.
Dr. Massimo Cristofanilli is an internationally renowned breast cancer researcher, clinician and director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals. With more than 25 years of clinical, basic science and educational experience, Dr. Cristofanilli also serves as deputy director of translational research at the KCC. Prior to joining Jefferson, Dr. Cristofanilli served as chairman of the department of medical oncology at Fox Chase Cancer Center in Philadelphia and head of the center’s Inflammatory Breast Cancer Clinic. Before that, he founded and served as executive director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic at The University of Texas M.D. Anderson Cancer Center in Houston, Texas.
Dr. Cristofanilli is a widely recognized leader in the translational research and treatment of inflammatory breast cancer (IBC). Moreover, he has recognized expertise in the development of novel diagnostic and prognostic markers in primary and metastatic breast cancer (MBC). His research aims to improve personalized medicine for breast cancer patients, focusing on molecular targeted agents, biomarkers and gene therapies, and bridging the gap between the bench and bedside in a more practical and smarter way. Dr. Cristofanilli is board certified by the American Board of Medical Oncology and the European Society for Medical Oncology.
Dr. Cristofanilli holds an M.D. from the University of La Sapienza in Rome, where he also completed a fellowship in medical oncology.
Dr. Ronald B. Natale is the director of the Lung Cancer Clinical Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center in Los Angeles. Dr. Natale is internationally renowned for his clinical research in lung and genitourinary cancers. He has published more than 250 articles and abstracts, authored chapters on lung cancer in several books and presented results of his research at cancer research meetings all over the world. Dr. Natale has developed or co-developed some the most widely used chemotherapy regimens in the world for small cell and non-small cell lung cancers (such as cisplatin + etoposide and carboplatin + paclitaxel), targeted agents in lung cancer including gefitinib, erlotinib and vandetanib, and the neoadjuvant MVAC regimen for localized bladder cancer. He has received numerous awards in recognition of his contributions to the treatment of lung and genitourinary cancers and has been cited as one of the best cancer doctors by Los Angeles Magazine, Good Housekeeping and each edition of Best Doctors in America since its inception.
Dr. Natale was a tenured faculty member at the University of Michigan, where he also served as associate director of the Comprehensive Cancer Center, and at the University of Southern California, where he served as associate director of medical oncology. Immediately prior to his current position, he served as senior research advisor and director of the National Lung Cancer Research Program for Aptium Oncology, Inc. His current work focuses on targeted therapies in lung cancer and mechanisms of action and resistance.
Dr. Natale holds a B.S. from the University of Michigan and an M.D. from Wayne State University School of Medicine in Detroit, where he also completed his medical residency. He completed a fellowship in hematology/oncology at the Memorial Sloan-Kettering Cancer Center in New York City and a research fellowship at the National Cancer Institute in Bethesda, Md.
Dr. Tony Reid currently serves as executive director, clinical trials of the Rebecca and John Moores Cancer Center at the University of California at San Diego (UCSD). He is currently a professor of medicine with primary specialty in cancer, gastrointestinal cancers, pancreatic cancer and hematology/blood diseases at UCSD. Dr. Reid has published broadly on the use of a new agent for the treatment of these malignancies and conducts a variety of clinical trials that utilize correlative studies to translate between important clinical and basic science observations. He has focused most of his work on early phase therapeutic clinical trials using gene therapy strategies to enhance the immune response to these malignancies. He was also the lead investigator on the original trials using Onyx-015 to treat colorectal cancer and has pioneered the use of adenoviral and vaccinia vectors for the treatment of cancer. Dr. Reid has been at the forefront of using interventional radiology to selectively deliver therapeutic directly to the tumor using the tumor's own vascular supply.
Dr. Reid has received national recognition for his work, including awards from the Interferon Society, the International Society of Gene Therapy and the Society for Interventional Radiology. He is on the review board of numerous prestigious journals including Nature Cancer Gene Therapy, Gene Therapyand Clinical Cancer Research.
Dr. Reid completed his residency and fellowship at Stanford University, where he also received his M.D. and a Ph.D. in biochemistry.
Dr. Max Rosen is chair of the department of radiology of both University of Massachusetts Memorial Medical Center and University of Massachusetts Medical School. He is also currently professor of radiology at the University of Massachusetts Medical School. Previously, he worked for 20 years at the Beth Israel Deaconess Medical Center in Boston (BIDMC), in both the interventional radiology and abdominal imaging sections. At BIDMC, he also was responsible for the development and management of several outpatient radiology practices sites, including a CT screening business, BeWell Body Scan LLC and a mobile ultrasound service.
Dr. Rosen’s research is focused on understanding the clinical effectiveness of imaging studies and Radiology process improvement. He is a fellow of the American College of Radiology, the American Heart Association and the Society of Interventional Radiology. He is the recipient of several awards in radiology, including the Young Investigator award from the Society of Cardiovascular and Interventional Radiology, The Memorial Award from the Society of Gastrointestinal Radiologists and a GE-AUR fellowship from the Association of University Radiologists. Dr. Rosen also serves on the scientific advisory board of Perceptive Informatics and the Boston Leadership Council of Health Leads USA.
Dr. Rosen graduated from Brown University and holds an M.D. from Tufts Medical School and an M.P.H. from the Harvard School of Public Health.
Dr. Lee Schwartzberg is a senior partner and medical director at The West Clinic, a 33-physician oncology, hematology and radiology practice in Memphis, Tenn. Dr. Schwartzberg is a professor of medicine and division chief of hematology/oncology at The University of Tennessee Health Science Center. He is also president and chief medical officer for ACORN Research.
Dr. Schwartzberg was awarded the 2004 Jefferson Award for community service. He was the founding editor-in-chief of the journal Community Oncology and the website OncologySTAT.com and serves on the editorial board of the Journal of Supportive Oncology. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer, targeted therapy and supportive care, having authored more than 110 research papers. He maintains a private practice in medical oncology focusing on breast cancer.
Dr. Schwartzberg attended medical college at the New York Medical College after receiving B.A. and M.S. degrees from State University of New York at Buffalo. He completed fellowship training in medical oncology and hematology at Memorial Sloan Kettering Cancer Center, where he also served as chief medical resident and was a founding member of the institutional ethics committee.
Dr. Fareeha Siddiqui is an associate professor of clinical oncology at the University of California at San Diego specializing in hematology/blood diseases.
Dr. Siddiqui was educated at Aga Khan University in Karachi, Pakistan and completed residencies and fellowship in the United States. Dr. Siddiqui is board certified in hematology, internal medicine and medical oncology.
Dr. N. Simon Tchekmedyian has practiced medical oncology in the Southern California community since 1986, after completing hematology and oncology training at the University of Maryland Cancer Center in Baltimore, Md. Dr. Tchekmedyian is a diplomat of the American Board of Internal Medicine and Medical Oncology, a fellow of the American College of Physicians, a clinical professor of medicine at the David Geffen School of Medicine at the University of California, Los Angeles, and a teaching head and director of oncology at St. Mary Medical Center. He is also founder and medical director of Pacific Shores Medical Group, one of the largest oncology practices in the country with a staff of more than 150 professionals in five offices in southern California.
Dr. Tchekmedyian’s pursuit of new treatments to improve the cure rate and to enhance the quality of life of cancer patients has been passionate and relentless. He has been a clinical investigator in more than 350 cancer research studies and has contributed more than 150 scientific publications to the medical literature. His original observations as reported to the American Association of Cancer Research in 1986 and published in the Journal of the American Medical Association in 1987 led to a new medication to reverse the lack of appetite and weight loss of patients. Highlights of his clinical research efforts include new life-saving therapies that specifically target cancer cells and thus provide increased efficacy and reduced side effects; examples include a variety of monoclonal antibodies and new molecules, several of which have been approved for clinical use. In many instances, these efforts allowed cancer patients in Long Beach to be the first ones in the nation to have access to and receive these new therapies. He has also contributed to new treatments for anemia, nausea, bone disorders and other complications associated with cancer.
Dr. Tchekmedyian has made more than 130 invited scientific presentations on new cancer treatments throughout the United States, as well as in more than 20 countries abroad. He has been repeatedly featured in the list of America’s Top Rated Physicians by the Washington, D.C.-based Center for the Study of Services, as well as in the list of Orange County Physicians of Excellence by the Orange County Medical Association and in the Guide to America’s Top Oncologists by the Consumers’ Research Council of America.
Dr. Tchekmedyian holds an M.D. from University School of Medicine in Montevideo, Uruguay.
Cynvenio CEO & Director
Chairman & Co‑Founder
Vice President at Livzon Pharmaceutical Group
Chief Investment Officer and Co-Founder of Syno Capital
Chief Executive Officer
Chief Scientific Officer